Cooper Companies (NASDAQ:COO) Releases Q4 2026 Earnings Guidance

Cooper Companies (NASDAQ:COO) updated its fourth quarter 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.050-1.090 for the period, compared to the consensus EPS estimate of 1.200. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Cooper Companies also updated its FY 2026 guidance to 4.510-4.550 EPS.

Cooper Companies Price Performance

NASDAQ:COO opened at $63.48 on Thursday. The firm has a market capitalization of $12.38 billion, a price-to-earnings ratio of 53.80, a PEG ratio of 1.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The business has a 50 day simple moving average of $72.42 and a 200-day simple moving average of $70.02. Cooper Companies has a 1 year low of $58.89 and a 1 year high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the previous year, the company posted $0.49 EPS. The company’s revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts forecast that Cooper Companies will post 4.63 EPS for the current year.

Cooper Companies declared that its board has approved a stock repurchase program on Wednesday, September 9th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on COO shares. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research note on Wednesday, May 27th. BNP Paribas Exane dropped their price target on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Cooper Companies in a research note on Friday, September 4th. Piper Sandler downgraded shares of Cooper Companies from an “overweight” rating to a “neutral” rating and set a $59.00 price target on the stock. in a report on Thursday. Finally, Mizuho set a $85.00 price objective on shares of Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $78.00.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal third-quarter adjusted EPS of $1.15, ahead of the $1.11–$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. Management also repurchased $339.1 million of stock during the quarter, supporting per-share value if executed effectively. CooperCompanies Completes Strategic Review
• Neutral Sentiment: GAAP EPS was $2.24, helped substantially by a $307.2 million discrete tax benefit related to the favorable completion of a U.K. tax examination. This benefit improves reported results but is not representative of recurring operating performance. CooperCompanies Reports Third-Quarter Results
• Negative Sentiment: CooperCompanies lowered fiscal 2026 adjusted EPS guidance to $4.51–$4.55, below the roughly $4.63 consensus, and set fourth-quarter EPS guidance at $1.05–$1.09 versus expectations near $1.20. Full-year revenue guidance of $4.229–$4.252 billion also implies modest growth.
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because potential offers were not sufficiently attractive. Investors appear disappointed that the company did not unlock value through a sale, particularly amid fertility-related litigation costs and competitive pressure in the IUD market. Reasons Cooper Companies Stock Is Under Pressure

Institutional Investors Weigh In On Cooper Companies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. CYBER HORNET ETFs LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter worth $36,000. MUFG Securities EMEA plc purchased a new stake in shares of Cooper Companies during the second quarter worth about $42,000. IFP Advisors Inc raised its holdings in shares of Cooper Companies by 2,647.8% in the third quarter. IFP Advisors Inc now owns 632 shares of the medical device company’s stock worth $43,000 after buying an additional 609 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Cooper Companies during the third quarter valued at $59,000. Finally, Quarry LP acquired a new position in shares of Cooper Companies in the fourth quarter valued at about $70,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.